Table 1.

Patients’ diabetes-related characteristics after receiving anti-PD-L1 therapy

	Case 1	Case 2
Anti-PD-L1 Therapy	Durvalumab	Atezolizumab
Time from initiation of therapy to onset of diabetes (weeks)	18	9
Clinical presentation	Vaginal candidiasis, recurrent bacterial cystitis, fatigue, polyuria, DKA	Fatigue, polyuria
Blood glucose at diagnosis	326 mg/dL	379 mg/dL
HbA1C at diagnosis	9.1% (76 mmol/mol)	8.2% (66 mmol/mol)
C-peptide (blood glucose)	0.4 ng/mL (142 mg/dL)*	1.1 ng/mL (386 mg/dL)* 0.6 ng/mL (336 mg/dL)†
GAD antibody	13 U/mL§	28.4 U/mL‡
Islet cell antibodies	Not available	Negative

*At diagnosis.

^†2 months after diagnosis.

‡Normal <1 U/mL.

§Normal <0.5 U/mL.

DKA, diabetic ketoacidosis; GAD, glutamic acid decarboxylase; HbA1C, glycated haemoglobin.; PD-L1, programmed cell death ligand-1.